Opko, Prolor deal

Opko will acquire Prolor Biotech in a stock deal that the companies said values Prolor at about $480 million. Under the deal, Prolor shareholders will receive 0.9951 Opko shares for every Prolor share held. The deal, which has been approved by the boards of both companies and is subject to shareholder approval, is slated to close next half. Barrington Research Associates Inc. advised Opko Health. Jefferies LLC advised Prolor and its strategic alternatives committee. Akerman Senterfitt acted as legal advisor to Opko. Greenberg Traurig P.A. acted as legal advisor to Prolor and DLA Piper LLC was legal advisor to the committee. ...